CNS Pharmaceuticals, Inc. financial data

Symbol
CNSP on Nasdaq
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 554% % 903%
Debt-to-equity 22% %
Return On Equity -130% % -119%
Return On Assets -107% % 79%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 620,290 shares -99%
Common Stock, Shares, Outstanding 574,580 shares -98%
Entity Public Float $8,780,000 USD 0%
Common Stock, Value, Issued $574 USD -98%
Weighted Average Number of Shares Outstanding, Basic 558,868 shares 1427%
Weighted Average Number of Shares Outstanding, Diluted 558,868 shares 1427%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $8,104,954 USD -33%
General and Administrative Expense $5,095,527 USD 1.6%
Operating Income (Loss) $13,200,481 USD 23%
Nonoperating Income (Expense) $129,353 USD 426%
Net Income (Loss) Attributable to Parent $13,071,128 USD 23%
Earnings Per Share, Basic 5,170 USD/shares 96%
Earnings Per Share, Diluted 5,170 USD/shares 96%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $9,864,087 USD 41%
Assets, Current $11,391,735 USD 54%
Property, Plant and Equipment, Net $3,107 USD 11%
Assets $11,869,258 USD 60%
Liabilities, Current $1,959,117 USD -52%
Liabilities $1,959,117 USD -52%
Retained Earnings (Accumulated Deficit) $94,319,466 USD -16%
Stockholders' Equity Attributable to Parent $9,910,141 USD 196%
Liabilities and Equity $11,869,258 USD 60%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,241,907 USD -1.6%
Net Cash Provided by (Used in) Financing Activities $9,828,121 USD 184%
Common Stock, Shares Authorized 25,000,000 shares -92%
Common Stock, Shares, Issued 574,580 shares -98%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9,864,087 USD 41%
Interest Paid, Excluding Capitalized Interest, Operating Activities $6,208 USD -6.3%
Deferred Tax Assets, Valuation Allowance $15,302,000 USD 20%
Depreciation $1,100 USD 34%
Deferred Tax Assets, Operating Loss Carryforwards $7,923,000 USD 19%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 416,667 shares -92%
Additional Paid in Capital $104,229,033 USD 23%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Interest Expense $14,994 USD 52%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%